Analyzes the current global markets for depressive and anxiety disorder treatments, with data for 2008, estimates for 2009, and projections, with compound annual growth rates (CAGRs), through 2014
Identifies the number of people globally diagnosed with depressive and anxiety disorders
Examines the markets for Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), tricyclic antidepressants, and other drugs used to treat depressive and anxiety disorders
Covers the market potential for novel antidepressants, including triple update inhibitors, and their mechanisms of action
Describes regulatory and economic issues
Reviews the industry and its structure, and the many companies involved in providing depressive and anxiety disorder medications.

INTRODUCTION

Study Goals and Objectives

The objectives of the study are to present a comprehensive look at disorders that affect the mind, specifically that cause depression and anxiety. An overall discussion of mental disorders associated with depression and anxiety is presented along with an in-depth discovery of the various diseases and disorders that present significant problems for individuals and society. Markets are divided according to drug type because several products are used in many different disorders.

REASONS FOR STUDY

This BBC study is presented to highlight the exciting area of mental health, specifically relating to depression and anxiety. Because in-depth study of the workings of the brain is a fairly new area of intense study, there are new and changing theories. The discovery of new mechanisms and chemicals in the brain has provided additional avenues for research and development of products that may alter the course of the diseases or modify the outcome. This study analyzes the current therapies for depression and anxiety and explores the new therapies that are in the pipeline to treat depression and anxiety. The study also addresses the many and varied issues and trends affecting the market. Because of the rapidly evolving climate of psychological disorders and the increasing knowledge of the workings of the brain, manufacturers of therapies for depressive and anxiety disorders must remain ever vigilant of the changing environment and strive to keep abreast of current and potential opportunities.

SCOPE OF STUDY

The report is designed to be a comprehensive business tool to provide an in-depth look at therapies for depression and anxiety. The geographic scope of the report is global with an emphasis on the United States. The report identifies the different disorders that manifest with depressive and anxiety symptoms; gives an explanation of the disorders; cites incidence; identifies specific drug types; presents current treatments, market size, and market participants; and presents potential treatments in research and development.

The market for therapies for depressive and anxiety disorders is divided into two areas:

Therapies for depression
Therapies for anxiety.

All markets are further broken down into specific types of products that are discussed in detail, measuring current and potential market size; identifying current and potential market drivers; detailing from 2006, 2007, 2008, 2009, and 2014; assessing current and potential competitors; and identifying current competitor market shares.

Methodology and Information Sources

The information and analysis presented in this BCC report are based on extensive first-hand interviews with primary executives, product managers, clinical specialists, and doctors involved in mental health and psychotherapeutics. Industry experts' perspectives as well as company reports were used in the market analysis. Background information was obtained from various government, business, medical journal, and trade magazines. Key information from published literature was used to conduct interviews with more than 21 industry participants to validate and obtain expert opinions on current and future trends. Interviews were also used to confirm and/or adjust market size and market share estimates as well as formulating market projections.

Chapter- 1: Introduction -- Complimentary
- Study Goals and Objectives
- Reasons for Study
- Scope of Study
- Methodology and Information Sources
- Analyst Credentials
- Related BCC Reports
- Disclaimer 3
Chapter-2: Executive Summary
- Historical Perspective of The Mental Health Industry
- Introduction to The Nervous System and Brain
- Introduction to The ... (Continued)
- Blood-Brain Barrier
- Demographics
- Table 1 World Population by Selected Geographical Region, 2008 - 2050 (Millions)
- Figure 1 World Population by Selected Geographical Region, 2008 - 2050 (Millions)
- Table 2 Estimated World Population by Age and Geographical Region, 2008 (Millions)
- Figure 2 Estimated World Population by Age and Geographical Region, 2008 (Millions)
- Table 3 Population over 65 by Year and Region, 2008-2050 (%)
- Figure 3 Population over 65 by Year and Region, 2008-2050
- Prevalence of Mental Disorders
- Table 4 Best Estimate 1-Year Prevalence Rates Based on Eca and Ncs, Ages 18-54 (%)
- Table 4 (Continued)
- Table 5 Percentage of Individuals 12 Years and Older with Depression by Demographic Characteristic - Age, Sex, and Race, U.S. 2006 (%)
- Table 6 Percentage of Individuals with Depression by Age and Poverty Status, United States 2006 (%)
- Table 7 Individuals 12 Year of Age and Older Reporting Difficulty with Their Work, Home, and Social Activities by Sex and Depression Severity, United States, 2006 (%)
- Table 8 Individuals 12 Years of Age and Older Contacting A Mental Health Professional in The past 12 Months, by Depression Severity, United States 2006 (%)
- Children and Adolescents
- Older Adults
- Costs of Mental Illness
- Table 9 Best Estimate Prevalence Rates Based on Epidemiological Catchment Area, Age 55+ (%)
- Depressive Disorders
- Major Depression
- Etiology and Neurobiology
- Table 10 Risk Factors for Major Depressive and Bipolar Disorders
- Table 11 Prefrontal Cortex and Serotonin Interconnections: Implications in Depression
- Table 11 (Continued)
- Clinical Manifestations
- Bipolar Disorder
- Etiology and Neurobiology
- Clinical Manifestations
- Bipolar I Disorder
- Bipolar Ii Disorder
- Bipolar Ii Disorder (Continued)
- Seasonal Affective Disorder
- Clinical Manifestations
- Anxiety Disorders
- Panic Disorder
- Etiology and Neurobiology
- Etiology and Neurobiology (Continued)
- Clinical Manifestations
- Generalized Anxiety Disorder
- Etiology and Neurobiology
- Etiology and Neurobiology (Continued)
- Clinical Manifestations
- Obsessive-Compulsive Disorder
- Etiology and Neurobiology
- Clinical Manifestations
- Specific and Social Phobias
- Table 12 Clinical Names for Common Phobias
- Post-Traumatic Stress Disorder
- Generic Influence
- Elderly Impact
- Depression
- Anxiety
- Children and Adolescent Impact
- Depression
- Symptoms of Depression in Children
- Symptoms of Depression in Children (Continued)
- Anxiety
- Alternative and Complementary Therapies
- St. John' S Wort (Hyperforin and Hypericin)
- Valerian Root
- 5-Htp
- Rhodiola Rosea
- Sam-E
- Bacopa
- Ginseng
- B Vitamins - B1, B3, B5, B6, B9, and B12
- Zinc
- Magnesium
- Kava Kava
- Overuse of Antidepressants - Another View
- Legislative Issues
- Compliance Issues
- Compliance Issues (Continued)
- Prescribing Trends
- Depression Risk Due to Brain Thinning
- Depression Risk Due to ... (Continued)
- Suicidal Behavior and Antidepressants
- Novel Approach in Teen Suicide
- Combination Therapy
- Remote Support for Depression
- Treatments and Products for Depressive Disorders
- Treatments and Products for...(Continued)
- Prescription Products
- Selective Serotonin Reuptake Inhibitors
- Side Effects
- Pharmacologics
- Serotonin-Norepinephrine Reuptake Inhibitors
- Tricyclic Antidepressants
- Chemical Aspects
- Mechanism of Action
- Actions and Side Effects
- Pharmacologics
- Monoamine Inhibitors
- Chemical Aspects
- Pharmacologics
- Side Effects
- Others
- Marketed Antidepressants
- Marketed Antidepressants (Continued)
- Marketed Antidepressants (Continued)
- Marketed Antidepressants (Continued)
- Table 13 Selected Marketed Antidepressant Drugs ($ Millions)
- Alternative Treatments
- Light Therapy
- Electroconvulsive Therapy
- Acupressure
- Acupuncture
- Biofeedback
- Nutrition
- Reflexology
- Self-Help Groups
- Animal-Assisted Therapies
- Expressive Therapies
- Art Therapy
- Dance/Movement Therapy
- Music/Sound Therapy
- Guided Imagery or Visualization
- Massage Therapy
- Technology-Based Applications
- Telemedicine
- Telephone Counseling
- Electronic Communications
- Radio Psychiatry
- Vagus Nerve Stimulation (Vns)
- Transcranial Magnetic Stimulation (Tms)
- Deep Brain Stimulation
- Treatments and Products for Anxiety Disorders
- Prescription Products
- Barbiturates
- Benzodiazepines
- Tricyclic Antidepressants
- Selective Serotonin Reuptake Inhibitors
- Serotonin-Norepinephrine Reuptake Inhibitors
- Effexor
- Cymbalta
- Antihistamines
- Anticonvulsants/Bipolar
- Lamictal
- Lithium
- Beta-Blockers
- Antipsychotics
- Abilify
- Buspar
- Geodon
- Risperdal
- Seroquel
- Zyprexa
- Table 14 Selected Marketedantianxiety Drugs
Chapter-3: Industry Overview
Chapter-4: Market Size and Growth
- Geodon
- Gepirone Er
- Risperdal Consta
- Saphris
- Seroquel Xr
- Trazodone Once Daily
- Agi0178
- Corlux
- Invega
- Lu Aa21004
- Lyrica
- Nuvigil
- Saredutant
- Vilazodone
- Table 27 Therapies in Development for Depression and Anxiety, 2009
- Novel Products in Development
Chapter-5: Research and Development
Chapter-6: Competitive Analysis
- Total Competitive Analysis
- Table 28 Total Competitive Analysis of Therapies for Depression and Anxiety Disorders by Drug Manufacturer Market Share, 2008 ($ Millions/%)
- Figure 16 Total Competitive Analysis of Therapies for Depression and Anxiety Disorders by Drug Manufacturer Market Share, 2008 (%)
- Depression Competitive Analysis
- Table 29 Competitive Analysis of Therapies for Depression Disorders by Drug Manufacturer Market Share, 2008 ($ Millions/%)
- Figure 17 Competitive Analysis of Therapies for Depression Disorders by Drug Manufacturer Market Share, 2008 (%)
- Table 30 Competitive Analysis of Therapies for Depression Disorders by The Top Four Drug Manufacturers' Market Share, 2008 ($ Millions/%)
- Figure 18 Competitive Analysis of Therapies for Depression Disorders by The Top Four Drug Manufacturers' Market Share, 2008 (%)
- Antianxiety Competitive Analysis
- Table 31 Competitive Analysis of Therapies for Anxiety Disorders by Drug Manufacturer Market Share, 2008 ($ Millions/%)
- Table 32 Competitive Analysis of Therapies for Anxiety Disorders by The Top Four Drug Manufacturer Market Share, 2008 ($ Millions/%)
- Figure 19 Competitive Analysis of Therapies for Anxiety Disorders by Drug Manufacturer Market Share, 2008 (%)
- Figure 20 Competitive Analysis of Therapies for Anxiety Disorders by The Top Four Drug Manufacturer Market Share, 2008 (%) 127
Chapter-7: Patent Analysis
Chapter-8: Company Profiles
Chapter-9: Appendix
Appendix A
- Alternative Approaches to Mental Health Organizations
Appendix B

Pharmaceutical Market Research

Therapies for Depressive and Anxiety Disorders